Publication: Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer.
Loading...
Identifiers
Date
2021-02-03
Authors
Blancas, I
Olier, C
Conde, V
Bayo, J L
Herrero, C
Zarcos-Pedrinaci, I
Carabantes, F
Baena-Cañada, J M
Cruz, J
Ruiz-Borrego, M
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Nature Publishing Group
Abstract
Goals of endocrine therapy for advanced breast cancer (ABC) include prolonging survival rates, maintaining the quality of life, and delaying the initiation of chemotherapy. We evaluated the effectiveness of fulvestrant as first-line in patients with estrogen receptor (ER)-positive ABC with relapse during or after adjuvant anti-estrogenic therapy in real-world settings. Retrospective, observational study involving 171 postmenopausal women with ER-positive ABC who received fulvestrant as first-line between January 2011 and May 2018 in Spanish hospitals. With a median follow-up of 31.4 months, the progression-free survival (PFS) with fulvestrant was 14.6 months. No differences were seen in the visceral metastatic (14.3 months) versus non-visceral (14.6 months) metastatic subgroup for PFS. Overall response rate and clinical benefit rate were 35.2% and 82.8%. Overall survival was 43.1 months. The duration of the clinical benefit was 19.2 months. Patients with ECOG performance status 0 at the start of treatment showed a significant greater clinical benefit rate and overall survival than with ECOG 1-2. Results in real-world settings are in concordance with randomized clinical trials. Fulvestrant continues to demonstrate clinical benefits in real-world settings and appears be well tolerated as first-line for the treatment of postmenopausal women with ER-positive ABC.
Description
MeSH Terms
Aged
Antineoplastic agents, hormonal
Biomarkers, tumor
Breast neoplasms
Estrogen receptor antagonists
Female
Fulvestrant
Humans
Middle aged
Neoplasm staging
Postmenopause
Prognosis
Receptors, estrogen
Retrospective studies
Treatment outcome
Antineoplastic agents, hormonal
Biomarkers, tumor
Breast neoplasms
Estrogen receptor antagonists
Female
Fulvestrant
Humans
Middle aged
Neoplasm staging
Postmenopause
Prognosis
Receptors, estrogen
Retrospective studies
Treatment outcome
DeCS Terms
Antagonistas del receptor de estrógeno
Antineoplásicos hormonales
Biomarcadores de tumor
Estadificación de neoplasias
Neoplasias de la mama
Posmenopausia
Pronóstico
Receptores de estrógenos
Resultado del tratamiento
Antineoplásicos hormonales
Biomarcadores de tumor
Estadificación de neoplasias
Neoplasias de la mama
Posmenopausia
Pronóstico
Receptores de estrógenos
Resultado del tratamiento
CIE Terms
Keywords
Antineoplastic agents, hormonal, Biomarkers, tumor, Breast neoplasms, Estrogen receptor antagonists
Citation
Blancas I, Olier C, Conde V, Bayo JL, Herrero C, Zarcos-Pedrinaci I, et al. Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer. Sci Rep. 2021 Feb 19;11(1):4274